Literature DB >> 19732052

A delay in radical nephroureterectomy can lead to upstaging.

Matthias Waldert1, Pierre I Karakiewicz, Jay D Raman, Mesut Remzi, Hendrik Isbarn, Yair Lotan, Umberto Capitanio, Karim Bensalah, Michael J Marberger, Shahrokh F Shariat.   

Abstract

STUDY TYPE: Prognosis (case series). LEVEL OF EVIDENCE: 4.
OBJECTIVE: To examine the association between the delay from diagnosis of upper-tract urothelial carcinoma (UTUC) to radical nephroureterectomy (RNU), and the pathological features and outcomes, as the decision to proceed to RNU for an individual patient is complex. PATIENTS AND METHODS: The records of 187 patients who had RNU were reviewed; the interval from diagnosis to RNU was analysed as both a continuous (months) and categorical variable (<3 vs > or =3 months). Logistic regression and survival analyses were used to evaluate the association between time from diagnosis to RNU with pathological characteristics and clinical outcomes.
RESULTS: The median time from diagnosis to RNU was 45 days (interquartile range 68). A delay from diagnosis to RNU analysed as a continuous variable was associated with advanced stage, higher grade, previous endoscopic procedure, tumour necrosis, infiltrative tumour architecture, and lymphovascular invasion (P = 0.034), but not disease recurrence or cancer-specific mortality. In the subgroup of patients (90, 48.1%) who had muscle-invasive disease (> or =pT2) a longer delay from diagnosis to RNU as a continuous variable was associated with advanced stage (P = 0.030), higher grade (P = 0.014), infiltrative tumour architecture (P = 0.044), lymphovascular invasion (P = 0.034), disease recurrence (P = 0.02), and cancer-specific mortality (P = 0.03).
CONCLUSIONS: Our data suggest that a delay in the interval from diagnosis to RNU is associated with more advanced disease stage. These findings might have important implications for trial design in the ongoing evaluation of neoadjuvant regimens. Timely consideration of definitive treatment for patients with high-risk UTUC is of high importance. Further studies are necessary to validate these hypothesis-generating findings.

Entities:  

Mesh:

Year:  2009        PMID: 19732052     DOI: 10.1111/j.1464-410X.2009.08821.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  33 in total

1.  Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma.

Authors:  Ricardo L Favaretto; Shahrokh F Shariat; Caroline Savage; Guilherme Godoy; Daher C Chade; Matthew Kaag; Bernard H Bochner; Jonathan Coleman; Guido Dalbagni
Journal:  BJU Int       Date:  2011-06-01       Impact factor: 5.588

Review 2.  [Upper tract urothelial carcinoma. An update on clinical and pathological prognostic factors].

Authors:  M Rink; M Adam; J Hansen; F K Chun; S A Ahyai; M Remzi; T Schlomm; O Engel; R Heuer; C Eichelberg; M Fisch; R Dahlem; S F Shariat
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

3.  Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy.

Authors:  Thomas F Chromecki; Behfar Ehdaie; Giacomo Novara; Karl Pummer; Richard Zigeuner; Christian Seitz; Armin Pycha; Richard K Lee; Eugene K Cha; Pierre I Karakiewicz; Casey Ng; Jay D Raman; Felix K Chun; Hans-Martin Fritsche; Kazumasa Matsumoto; Wassim Kassouf; Thomas J Walton; Patrick J Bastian; Juan I Martínez-Salamanca; Douglas S Scherr; Shahrokh F Shariat
Journal:  World J Urol       Date:  2011-04-17       Impact factor: 4.226

4.  [Impact of diagnostic ureteroscopy and biopsy on radical nephroureterectomy of upper tract urothelial carcinoma].

Authors:  R Z Ma; H Z Xia; M Lu; Z Y Zhang; Q M Zhang; J Lu; G L Wang; L L Ma
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-08-18

5.  Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?

Authors:  Mesut Remzi; Shahrokh Shariat; Wilhelm Huebner; Harun Fajkovic; Christian Seitz
Journal:  Ther Adv Urol       Date:  2011-04

Review 6.  Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.

Authors:  Atiqullah Aziz; Jakub Dobruch; Kees Hendricksen; Luis A Kluth; Andrea Necchi; Aidan Noon; Michael Rink; Florian Roghmann; Roland Seiler; Paolo Gontero; Wassim Kassouf; Shahrokh F Shariat; Evanguelos Xylinas
Journal:  World J Urol       Date:  2017-01-10       Impact factor: 4.226

Review 7.  Prognostic factors for upper urinary tract urothelial carcinoma.

Authors:  Thomas F Chromecki; Karim Bensalah; Mesut Remzi; Grégory Verhoest; Eugene K Cha; Douglas S Scherr; Giacomo Novara; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2011-07-05       Impact factor: 14.432

8.  Specific body mass index cut-off value in relation to survival of patients with upper urinary tract urothelial carcinomas.

Authors:  Teruo Inamoto; Kazumasa Komura; Toshikazu Watsuji; Haruhito Azuma
Journal:  Int J Clin Oncol       Date:  2011-07-08       Impact factor: 3.402

Review 9.  Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival.

Authors:  Vincent Bourgade; Sarah J Drouin; David R Yates; Jerôme Parra; Marc-Olivier Bitker; Olivier Cussenot; Morgan Rouprêt
Journal:  World J Urol       Date:  2013-03-02       Impact factor: 4.226

10.  The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database.

Authors:  Laurent Nison; Morgan Rouprêt; Grégory Bozzini; Adil Ouzzane; François Audenet; Géraldine Pignot; Alain Ruffion; Jean-Nicolas Cornu; Sophie Hurel; Antoine Valeri; Mathieu Roumiguie; Thomas Polguer; Nicolas Hoarau; Olivier Mérigot de Treigny; Evanguelos Xylinas; Alexandre Matte; Stéphane Droupy; Pierre Olivier Fais; Aurélien Descazeaud; Pierre Colin
Journal:  World J Urol       Date:  2012-10-16       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.